文献速递心力衰竭与心肌病

替尔泊肽对射血分数保留心衰合并肥胖患者临床轨迹的影响

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
PubMed 文献 · Circulation · 2024-11-18

该双盲随机对照试验纳入731例射血分数≥50%、BMI≥30 kg/m²的心衰患者,比较替尔泊肽(滴定至15 mg每周皮下注射)与安慰剂的疗效。中位随访104周显示,替尔泊肽在死亡与心衰恶化复合终点、堪萨斯城心肌病问卷评分、6分钟步行距离、EQ-5D-5L健康状态指数、患者总体印象严重程度、NYHA分级及心衰药物使用方面均产生一致且有意义的改善。

要点

  • 替尔泊肽降低心血管死亡或心衰恶化复合终点风险(HR 0.41–0.67)。
  • 52周时KCCQ-CSS评分提高6.9分,6分钟步行距离增加18.3米。
  • 替尔泊肽组NYHA分级和患者总体印象趋向更优,且心衰药物需求更少。

核心结论

  • 在射血分数保留心衰合并肥胖患者中,替尔泊肽在多个互补领域产生全面且有意义的改善,包括健康状况、生活质量、功能 capacity、运动耐受性和幸福感,并减少症状和药物负担。

研究设计与样本

  • 双盲随机对照试验,纳入731例NYHA II–IV级、射血分数≥50%、BMI≥30 kg/m²的心衰患者,随机分配至替尔泊肽组(n=364,滴定至15 mg每周皮下注射)或安慰剂组(n=367),中位随访104周(四分位距66–126周)。

主要发现

  • 与安慰剂相比,替尔泊肽在死亡和心衰恶化事件的所有复合分析中均显示一致获益(风险比0.41–0.67)。
  • 52周时,替尔泊肽使KCCQ-CSS评分提高6.9分(95%CI 3.3–10.6;P<0.001),6分钟步行距离增加18.3米(95%CI 9.9–26.7;P<0.001),EQ-5D-5L指数提高0.06(95%CI 0.03–0.09;P<0.001)。
  • 替尔泊肽组患者总体印象严重程度总体健康评分趋向更优(比例优势比1.99,95%CI 1.44–2.76),NYHA分级趋向更优(比例优势比2.26,95%CI 1.54–3.31),两者P均<0.001,且心衰药物使用更少(P=0.015)。
  • hierarchical复合终点显示获益(win ratio 1.63,95%CI 1.17–2.28;P=0.004)。

临床怎么用

  • 对于射血分数保留心衰合并肥胖患者,替尔泊肽可考虑用于改善症状、功能状态和生活质量,并可能减少心衰药物负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients. METHODS: We randomized (double-blind) 731 patients with class II to IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m2 to tirzepatide (titrated up to 15 mg SC weekly; n=364) or placebo (n=367) added to background therapy for a median of 104 weeks (quartile 1, 66; quartile 3, 126 weeks). The primary end points were whether tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The current expanded analysis included sensitivity analyses of the primary end points, 6-minute walk distance, EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health score, New York Heart Association class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and 6-minute walk distance. RESULTS: Patients were 65.2±10.7 years of age; 53.8% (n=393) were female; body mass index was 38.2±6.7 kg/m2; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was 53.5±18.5; 6-minute walk distance was 302.8±81.7 m; and 53% (n=388) had a worsening heart failure event in the previous 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time to first event (hazard ratios, 0.41-0.67). At 52 weeks, tirzepatide increased the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score by 6.9 points (95% CI, 3.3-10.6; P<0.001), 6-minute walk distance 18.3 meters (95% CI, 9.9-26.7; P<0.001), and EQ-5D-5L 0.06 (95% CI, 0.03-0.09; P<0.001). The tirzepatide group shifted to a more favorable Patient Global Impression of Severity Overall Health score (proportional odds ratio, 1.99 [95% CI, 1.44-2.76]) and New York Heart Association class (proportional odds ratio, 2.26 [95% CI, 1.54-3.31]; both P<0.001) and required fewer heart failure medications (P=0.015). The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio, 1.63 [95% CI, 1.17-2.28]; P=0.004). CONCLUSIONS: Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04847557.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zile, Borlaug, Kramer, et al. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 2024. PMID: 39556714. doi:10.1161/CIRCULATIONAHA.124.072679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。